A Phase 1b First-in-human Dose Escalation and Expansion Multicenter Study of XMT-1660 in Participants with Solid Tumors

Brief description of study

If you are diagnosed with stage 4 tumor of any solid origin, for example; breast, endometrial, ovarian, fallopian tube, cervix, vaginal or primary peritoneal cancer then you have the opportunity to participate in this study. This study has two parts: Part one will look at the tolerability and safety of XMT-1660 (a DAR-6 Dolasynthen-based antibody drug conjugate) in order to determine the maximum tolerated and/or recommended doses of this investigational drug. Part two of this trial will further evaluate the way this drug affects a person's body and how participants respond to the drug with advanced/metastatic cancer.

The study drug XMT-1660 is investigational, the FDA has provided permission to test this agent in the current trial.

Clinical Study Identifier: s22-00389
ClinicalTrials.gov Identifier: NCT05377996

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.